Results 181 to 190 of about 149,997 (261)

Postoperative radiotherapy versus postoperative radiochemotherapy after surgery of salivary gland cancer: a systematic review and meta-analysis. [PDF]

Sci Rep
Wilhelmy A, Schlattmann P, Guntinas-Lichius O.   +2 more
europepmc   +1 more source

How much is enough? Defining the critical resection margin in myxofibrosarcoma. [PDF]

World J Surg Oncol
Wallner C, Drysch M, Reinkemeier F, Schmidt S, Sogorski A, Stricker I, Dadras M, Lehnhardt M, Puscz F.   +8 more
europepmc   +1 more source

Comparative effectiveness of different adjuvant therapy modalities for stage IIIA-N2 non-small cell lung cancer following complete resection: a retrospective analysis. [PDF]

Am J Cancer Res
Li B, Yang H, Li H, Li S.
europepmc   +1 more source

Effect of the new FIGO 2023 staging system on stage distribution and adjuvant therapies in endometrial cancer: A retrospective cohort study. [PDF]

Turk J Obstet Gynecol
Erkmen AD, Arkan K.
europepmc   +1 more source

Adenoid cystic carcinoma of the uterine cervix with metastasis 10 years postsurgery: Case report and literature review. [PDF]

Radiol Case Rep
Han Y, Zhou J.
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Prognostic Factors and Survival in Surgically Treated Stage III Non-Small Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study. [PDF]

Curr Oncol
Elma B, Kumbasar HZ, Dogan I, Ulusan A, Sanli M, Isik AF.   +5 more
europepmc   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol. [PDF]

BMJ Open
Koroki K, Wakatsuki M, Ogasawara S, Makishima H, Watabe T, Anzai H, Fujiya M, Sawada M, Tsuchiya T, Katayama K, Yoshino R, Izai R, Akatsuka T, Miwa C, Yonemoto T, Yumita S, Inoue M, Nakamura M, Kanogawa N, Nakamoto S, Takahashi K, Ozawa Y, Inaba Y, Kurokawa T, Isozaki T, Takahashi A, Kato J, Ohtsuka M, Ohno T, Ueno Y, Furuse J, Kudo M, Hanaoka H, Ishikawa H.   +33 more
europepmc   +1 more source